Web Exclusives

Using a Team Approach to Tackle Opioid Abuse in Patients with Cancer

“Communication is a beautiful thing, and we stress that a lot in our clinic. The longer a patient is on pain medicine, the harder it is to come off of it and the more it’s going to predict issues later on, so we have to continue to be vigilant,” Ms. Edwards

Immunotherapy Combination Shows Durable Responses in Mismatch Repair–Deficient Metastatic Colorectal Cancer

San Francisco, CA—The immunotherapy combination of nivolumab (Opdivo) and ipilimumab (Yervoy) provides durable clinical benefit in patients with previously treated DNA mismatch repair–deficient (dMMR)/microsatellite instability-high (MSI-H) metastatic colorectal cancer (CRC).

Combining Immunotherapy and Radiotherapy Shows Good Synergy

As the number of patients receiving immune checkpoint blockade grows, the combination of radiation and immunotherapy has become increasingly relevant, particularly in the palliative care setting, where radiation therapy is used to treat painful lesions or brain metastases.

NCCN Issues First Guideline for Immunotherapy-Related Adverse Events

The National Comprehensive Cancer Network (NCCN)’s first guideline (version 1.2018) for the management of side effects from immunotherapy recognizes “a new spectrum of adverse events” in patients who are receiving immune checkpoint inhibitor therapy, said John A. Thompson, MD, Director, Phase I Clinical Trials Program, Fred Hutchinson Cancer Research Center, [ Read More ]

Quizartinib Significantly Improves Survival Over Chemotherapy in Patients with Relapsed/Refractory AML and FLT3-ITD Mutation

New results from the international, randomized, phase 3 clinical trial QuANTUM-R show that the targeted drug quizartinib, an oral, selective FLT3 inhibitor, significantly extended overall survival compared with chemotherapy in patients with relapsed or refractory acute myeloid leukemia (AML) and the FLT3-ITD mutation, the most common FLT3 gene mutation, affecting [ Read More ]

Breaking News: Sellas Announces Promising Data on NeuVax in Combination with Herceptin in HER2 1+/2+ Breast Cancer

This week Sellas Life Sciences Group announced data from a study of NeuVax (nelipepimut-S) in combination with Herceptin (trastuzumab) in patients with HER2 1+/2+ breast cancer. All node-negative (N0) patients had triple-negative breast cancer (TNBC), as did the majority of patients with low-volume nodal disease (N1); the remainder of the [ Read More ]

Mogamulizumab, Anti-CCR4 Antibody, Improves Survival in Patients with Advanced Cutaneous T-Cell Lymphoma

Atlanta, GA—Mogamulizumab, a monoclonal antibody targeting CC chemokine receptor type 4 (CCR4), significantly reduced the risk for disease progression or death in patients with untreated cutaneous T-cell lymphoma (CTCL) compared with vorinostat (Zolinza), reported Youn H. Kim, MD, Director, Multidisciplinary Cutaneous Lymphoma Program, Stanford Medicine, California, at ASH 2017. Patients [ Read More ]

First-in-Class Sotatercept Improves Hemoglobin Levels in Anemic Patients with Myelofibrosis

Atlanta, GA—Sotatercept, an investigational activin receptor IIA ligand trap, when used alone or in combination with ruxolitinib (Jakafi), safely increases hemoglobin levels in patients with myeloproliferative neoplasm–associated myelofibrosis, according to data from a phase 2, investigator-initiated clinical trial, presented at ASH 2017. Ruxolitinib is the only medication approved by the [ Read More ]

Ivosidenib, New IDH1 Inhibitor, Elicits Complete Response in Relapsed Acute Myeloid Leukemia

Atlanta, GA—Treatment with ivosidenib, an IDH1 inhibitor, resulted in an objective response rate (ORR) of 41.6% in a phase 1 dose-escalation and expansion clinical trial in patients with relapsed or refractory acute myeloid leukemia (AML) and IDH1 mutation. Ivosidenib induced a complete response (CR) or a CR with a partial [ Read More ]

CAR T-Cell Immunotherapy Makes Strides in Multiple Myeloma, with Durable Remission

Chicago, IL—The era of immunotherapy in multiple myeloma is near. Two presentations at ASCO 2017 demonstrated that cellular therapy can steer immune reconstitution against multiple myeloma. Edward A. Stadtmauer, MD, Chief, Hematologic Malignancies Section, Abramson Cancer Center, University of Pennsylvania, Philadelphia, reviewed cellular strategies, from vaccine-primed T-cell transfer after autologous [ Read More ]

Sign me up!